Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hereditary Angioedema Type I and II Clear all
Completed No phase listed Observational
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant low dose, Deucrictibant high dose, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Placebo, KVD900 600 mg, KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced May 21, 2026, 11:51 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, Hereditary Angioedema - Type 3, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema Type III, Hereditary Angioedema (HAE), Hereditary Angioedema Type I and II
Interventions
deucrictibant
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 11:51 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Inapplicable
Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced May 21, 2026, 11:51 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 600 mg, KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 11:51 PM EDT
Approved For Marketing No phase listed Expanded access
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Sebetralstat
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years and older
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900, Placebo
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Scottsdale, Arizona • Centennial, Colorado • Chevy Chase, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 150 mg, KVD900 300 mg, KVD900 600 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 21, 2026, 11:51 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Angioedema, Hereditary, Types I and II
Interventions
KVD824, Placebo to KVD824
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced May 21, 2026, 11:51 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 600 mg, Drug: KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema, HAE, Prophylaxis
Interventions
BCX7353
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
C1-esterase inhibitor - single intravenous dose, C1-esterase inhibitor - subcutaneous low dose, C1-esterase inhibitor - subcutaneous medium dose, C1-esterase inhibitor - subcutaneous high dose
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Atlanta, Georgia • Chevy Chase, Maryland • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced May 21, 2026, 11:51 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Ecallantide subcutaneous dosing
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced May 21, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
C1-esterase inhibitor
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced May 21, 2026, 11:51 PM EDT